Literature DB >> 20931272

Successful tocilizumab treatment in a patient with adult-onset Still's disease complicated by chronic active hepatitis B and amyloid A amyloidosis.

Dai Kishida1, Yasuaki Okuda, Makoto Onishi, Masashi Takebayashi, Kenichiro Matoba, Kazuo Jouyama, Akihiro Yamada, Naoya Sawada, Sho Mokuda, Kiyoshi Takasugi.   

Abstract

We report successful tocilizumab (TCZ) use in a patient with adult-onset Still's disease (AOSD) complicated by chronic hepatitis B (CHB) and AA amyloidosis (AAA). Treatments with corticosteroid and various types of immunosuppressants were unsuccessful. Aggravation of CHB ensued, and entecavir was started. Normalisation of liver function and hepatitis B virus (HBV) DNA were confirmed. TCZ was then started. His arthritis and AAA improved dramatically. TCZ is an excellent treatment for refractory AOSD and is feasible in an HBV-infected patient.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20931272     DOI： 10.1007/s10165-010-0365-8

Source DB:  PubMed          Journal:  Mod Rheumatol        ISSN： 1439-7595            Impact factor:   3.023


  14 in total

1.  Unchanged serum viral load and liver function during tocilizumab treatment in a patient with rheumatoid arthritis and hepatitis C virus infection.

Authors:  Takao Nagashima; Akihito Maruyama; Yasuyuki Kamata; Seiji Minota
Journal:  Rheumatol Int       Date:  2011-07-23       Impact factor: 2.631

Review 2.  Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs.

Authors:  Francesca De Nard; Monica Todoerti; Vittorio Grosso; Sara Monti; Silvia Breda; Silvia Rossi; Carlomaurizio Montecucco; Roberto Caporali
Journal:  World J Hepatol       Date:  2015-03-27

Review 3.  Successful treatment of adult-onset Still's disease with tocilizumab monotherapy: two case reports and literature review.

Authors:  Ryota Sakai; Hayato Nagasawa; Eiko Nishi; Ayumi Okuyama; Hirofumi Takei; Takahiko Kurasawa; Tsuneo Kondo; Koji Nishimura; Yuichiro Shirai; Tatsuya Ito; Hideto Kameda; Tsutomu Takeuchi; Koichi Amano
Journal:  Clin Rheumatol       Date:  2012-01-04       Impact factor: 2.980

Review 4.  Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations.

Authors:  Shunsuke Mori; Shigetoshi Fujiyama
Journal:  World J Gastroenterol       Date:  2015-09-28       Impact factor: 5.742

5.  Diagnosis of amyloidosis and differentiation from chronic, idiopathic enterocolitis in rhesus (Macaca mulatta) and pig-tailed (M. nemestrina) macaques.

Authors:  Kelly A Rice; Edward S Chen; Kelly A Metcalf Pate; Eric K Hutchinson; Robert J Adams
Journal:  Comp Med       Date:  2013-06       Impact factor: 0.982

Review 6.  Management of rheumatic disease with comorbid HBV or HCV infection.

Authors:  Dimitrios Vassilopoulos; Leonard H Calabrese
Journal:  Nat Rev Rheumatol       Date:  2012-05-08       Impact factor: 20.543

7.  Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions.

Authors:  Atsushi Ogata; Toshio Tanaka
Journal:  Int J Rheumatol       Date:  2012-01-18

Review 8.  Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases.

Authors:  Toshio Tanaka; Tadamitsu Kishimoto
Journal:  Int J Biol Sci       Date:  2012-10-24       Impact factor: 6.580

9.  Adult-Onset Still's Disease: From Pathophysiology to Targeted Therapies.

Authors:  Clio P Mavragani; Evangelos G Spyridakis; Michael Koutsilieris
Journal:  Int J Inflam       Date:  2012-06-26

Review 10.  Tocilizumab in the treatment of the adult-onset Still's disease: current clinical evidence.

Authors:  Hubert de Boysson; Jérome Février; Amélie Nicolle; Christophe Auzary; Loïk Geffray
Journal:  Clin Rheumatol       Date:  2012-10-30       Impact factor: 3.650
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.